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We present a case of asymptomatic pheochromocytoma with severe hypertension and 
tachycardia evoked by the administration of pancuronium bromide, a nondepolarizing 
muscle relaxant which has been used commonly in the anesthetic management of patients 
with pheochromocytoma. 
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INTRODUCTION 
Pancuronium bromide has been recom-
mended as a safe and effective muscle 
relaxant for patients with pheochromo-
cytoma. However, it has been said to 
release catecholamines from the adre-
nergic nerve endings, and to block the 
re-uptake of noradrenaline by the adre-
nergic nerve endings as well. Thus, this 
drug may cause striking hypertension and 
tachycardia during anesthesia or surgical 
intervention for pheochromocytoma. We 
describe a case of an asymptomatic pheo-
chromocytoma associated with severe 
hypertension and tachycardia following 
pancuronium bromide administration. 
CASE REPORT 
A 33-year-old man had been followed 
for an asymptomatic and nonfunctioning 
adrenal tumor at a medical service of a 
certain university hospital since Nove-
mber of 1981. However, the patient was 
afraid of malignancy, and the possibility 
of a malignant adrenal tumor could not 
be excluded after further examinations 
at the medical service of Ishikawa Prefe-
ctural Central Hospital. He was then 
referred to and admitted at our Urology 
Clinic for an operation on July 1, 1982. 
There was no personal history of hyper-
tension, palpitation, headache or sweat-
ing. The patient was well-nourished, 184 
cm tall, 87 kg in weight; his temperature, 
respiration, pulse rate (72/min.) and blood 
pressure (120/90 mm.Hg.) were all normal. 
Laboratory studies revealed a normal 
electrolyte value, and normal liver and 
renal functions. Endocrinological studies 
of the blood revealed slight elevation of 
plasma renin activity to 2.4 ng/ml/h. 
(normal range, NR: O. 1 ~2. 0) and of 
noradrenaline to 436 pg/ml (NR: 40 to 
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350). Endocrinologic studies of the urine 
revealed a slightly elevated level of nora-
drenaline (192 meg/day, NR: 1O~90), dop-
amine (730 meg/day NR: 100~ 700), and 
vanillyl mandelic acid (15. 8 meg/day NR: 
2~ 12). The functions of the thyroid, 
pancreatic islet cells, adrenal cortex and 
hypopituitary gland were within the nor-
mal ranges. An electrocardiogram and 
a chest plain film revealed no abnor-
mality, and the circulating blood volume 
was also within normal limits. Computer-
ized tomography unveiled a round mass 
in the left suprarenal fossa, which was 
depicted well after an intravenous inject-
ion of contrast medium. On July 19, 
1982, left adrenalectomy was performed 
under general anesthesia using enflurane-
nitrous oxide-oxygen. Anesthesia record 
(Fig. 1). Just before anesthesia the blood 
pressure was 120/70 mmHg. and pulse rate 
was 68/min. Stable and sufficient ane-
sthesia was confirmed after the induction, 
and thereafter 7.5 mg of pancuronium 
bromide was injected to obtain efficient 
muscle relaxation for the operation. Just 
after drug administration the blood 
pressure was markedly increased to the 
level of 220 mmHg. and ventricular 
tachycardia and bigeminal pulses appe-
ared together. To treat these attacks, 100 
mg lidocaine hydrochloride, 1 mg pro-
pranol hydrochloride (Inderal®) and 10 
mg phentolamine mesylate (Regitinel!t) 
were injected; the hypertensive attack 
and bigeminal pulse subsided. Blood 
pressure, in the operation, had been 
maintained between 140 and 160 mmHg 
without phentolamine mesylate but 0.5 
mg of this drug at the start of the 
operation. Surgery record. The adrenal 
gland was approached through a left flank 
incision and dissected easily without any 
surrounding retroperitoneal tissue at-
tached. The adrenal gland including the 
tumor weighed 33.6 g. Microscopic appear-
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ance. Histological examination revealed 
a pheochromocytoma with no findings 
suggesting malignancy, that is capsular 
infiltration or mitosis. Postoperative course. 
Convalescence was uneventful and the 
noradrenaline values were normalized 
one month after the left adrenalectomy. 
DISCUSSION 
Pheochromocytoma is classified into 3 
types consisting of sustained, paroxymal 
and asymptomatic types according to the 
clinical manifestations. Approximately 10 
per cent of pheochromocytoma patients 
remain asymptomatic!), and several ex-
pressions such as "atypical", "nonfuncti-
oning" and "masked" are used in place 
of "asymptomatic." Sakamoto and asso-
ciates2), found the same granules secre-
ting catecholamines in an asymptomatic 
pheochromocytoma as those in a function-
ing pheochromocytoma, and confirmed 
Yamada's hypothesis3) that a release of 
catecholamines into the blood circulation 
was not necessarily related to the amount 
of catecholamine production or storage. 
Concerning the pathophysiology, Yama-
da4) found that in asymptomatic pheochro-
mocytoma, the secreting granules were 
poorly launched from the tumor cells. 
On the other hand, Taubman and asso-
ciates5) reported a case of an asympto-
matic catecholamine-secreting pheochro-
mocytoma, and Ho and associates6) de-
scribed normotensive familial pheochro-
mocytoma with predominant noradrena-
line secretion. Satoh and associates7) gave 
an account of decreased sensitivity to 
catecholamines for asymptomatic phe-
ochromocytoma patients. Because no 
hypertensive attack occurred in our case 
even though the tumors had been removed 
without any special attention paid during 
the operation, it was assumed that the 
pheochromocytoma did not secrete cate-
cholamines into the blood circulation, or 
that the patient were not so sensitive to 
the catecholamines even if they had been 
released from the tumor into the blood 
circulation during the operation. There 
is still a huge controversy over the patho-
genesis of hypertension In patients with 
pheochromocytoma. 
Until now pancuronium bromide has 
not been known to cause histamine release 
and block the sympathetic ganglia8). But, 
Jones and Hill9) have described a case of 
pheochromocytoma showing severe hyper-
tension and tachycardia associated with 
pancuronium bromide, and emphasized 
that pancuronium bromide has a catecho-
lamine-releasing action and causes po-
tentially life-threatening hypertension in 
the patient undergoing surgery for the 
removal of a pheochromocytoma. Pancur-
onium bromide has been considered to 
provoke short-lasting cardiovascular sti-
mulation10) and vagolytic action on the 
heartll) since both adrenaline and espe-
cially noradrenaline have been found to 
be augmented after pancuronium bromide 
administrationI2). Dobkin and associates l3) 
also reported transient ventricular arrhyth-
mia in 5 patients and Stoetling14l reported 
premature ventricular contractions in 2 
patients, after pancuronium bromide was 
administered in the anesthesia. I vankovich 
and associates l5) and Domenech and asso-
ciates l6) concluded that pharmacologically 
pancuronium bromide acts on the post-
ganglionic nerve endings, causes release 
of catecholamines and inhibits the re-
uptake of noradrenaline by the adrenergic 
nerve endings. It was suspected that in 
our case the elevated catecholamine level 
in the blood circulation or at the sympa-
thetic nerve endings, was evoked rapi-
dly by an intravenous injection of more 
than a saturating dose of pancuronium 
bromide, which transiently was more than 
the amount required to cause secretion 
of catecholamine granules from the tumor 
or more than the amount causing sensi-
tivity of the sympathetic nerve endings 
to catecholamines. We insist that the in-
fluence of nitrous oxide gas or enflurane 
was considered and we conclude that there 
was a causal relationship between pan cur-
onium bromide, hypertension, tachycardia 
and pheochromocytoma, but we believe 
that pancuronium bromide administration 
was the most probable cause of the hyper-
712 Acta Urol. Jpn. Vol. 30 No.5, 1984 
tensive attack in our case. Thus sufficient 
attention should be paid when admin-
istering pancuronium bromide to patients 
with a pheochromocytoma. 
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麻酔導入時のpancuroniumbromideの投与によ
り著明な高血圧および頻脈をきたした興味ある無症候
性褐色細胞腫の1例を報告する.
症例は33歳男子で,主訴は左副腎腫瘍の精査,家族歴
および既往歴に特記すべきことなし,右季肋下部不快
感で某医でCTス キャンを受けたところ,左 副腎腫
瘍を指摘された.諸 検査成績で尿中カテコラミンが軽
度に上昇する以外に異常はない.7月1日手術目的で入
院し,同19日左副腎摘除術を受けた.エトレンおよび笑
気で十分な全身麻酔をおこなった後,pancuronium
7.5mgを筋弛緩を得るため投与したところ急激な血
圧上昇(220mmHg),2段脈,心 室性頻脈を認めた.
Lidocain（R）,Inderal（R）,Regitine（R）の投与にて症状は
消失した.手 術中に特記すべ き血圧の変動は認められ
なかった.腫 瘍の重 さは33.69で,組織所見は褐色
細胞腫であった.
福色細胞腫における高血圧の発症機序についてはい
まだ不明な点が多い.交感神経刺激作用を有するとさ
れるpanecuroniumbromideにより高血圧症をき
たしたことは本症の高血圧発症を考える上で興味深 く,
若干の文献的考察を加えた.
